Akebia Therapeutics (AKBA) Return on Equity [ROE] (2014 - 2026)
Akebia Therapeutics (AKBA) reported Return on Equity [ROE] of -113.24% for Q2 2026, up 22.37 percentage points from -135.62% a year earlier but down 44.86 percentage points from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Return on Equity [ROE] (2014 - 2026) Analysis & Trends
For FY2022, Akebia Therapeutics posted Return on Equity [ROE] of -237.83%, down 60.66 percentage points from FY2021.
- Return on Equity [ROE] has declined for four consecutive years, with a five-year change of -160.56 percentage points (FY2017 to FY2022).
- By year, Return on Equity [ROE] came in at -177.17% in FY2021 (-56.39 pp), -120.79% in FY2020 (-66.42 pp), -54.37% in FY2019 (-16.50 pp) and -37.86% in FY2018 (+39.41 pp).
- Five-year quarterly Return on Equity [ROE] spans a low of -1197.72% in Q4 2022 and a high of -14.41% in Q4 2025.
- Per Business Quant data, the three quarters before Q2 2026 came in at -68.39% (Q1 2026), -14.41% (Q4 2025) and -44.92% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 74.39% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | - |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 5.63% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 21.60% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 72.13% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -31.17% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 4.66% |
| 10 | Akebia Therapeutics | 149.86 Mn | -512.48 Mn | 30.54 Mn | -196.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -196.36% |
| Jun 30, 2026 | -113.24% |
| Mar 31, 2026 | -68.39% |
| Dec 31, 2025 | -14.41% |
| Sep 30, 2025 | -44.92% |
| Jun 30, 2025 | -135.62% |
| Dec 31, 2022 | -1,380.96% |
| Sep 30, 2022 | -467.08% |
| Jun 30, 2022 | -398.39% |
| Mar 31, 2022 | -569.16% |
| Dec 31, 2021 | -267.13% |
| Sep 30, 2021 | -192.79% |
| Jun 30, 2021 | -154.92% |
| Mar 31, 2021 | -171.81% |
| Dec 31, 2020 | -136.87% |
| Sep 30, 2020 | -113.61% |
| Jun 30, 2020 | -100.60% |
| Mar 31, 2020 | -67.90% |
| Dec 31, 2019 | -64.94% |
| Sep 30, 2019 | -49.61% |
API Access
Akebia Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();